• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic launches DCB clinical trial for below-the-knee peripheral artery disease

March 9, 2017 By Sarah Faulkner

Medtronic launches DCB clinical trial for below-the-knee peripheral artery diseaseMedtronic (NYSE:MDT) said today that it launched a clinical trial to evaluate the use of its In.Pact paclitaxel-coated percutaneous transluminal angioplasty balloon catheter in patients with below-the-knee peripheral arterial disease.

The company treated its 1st patient in the In.Pact BTK study, performing the procedure on a patient with critical limb ischemia.

“The 1st patient enrollment in the In.Pact BTK study marks a landmark milestone in identifying a treatment option for below-the-knee PAD,” Dr. Antonio Micari of Maria Cecilia Hospital said in prepared remarks. “Given the chronic nature and co-morbidities of this disease, there is a critical need for treatment options that are safe and durable. I look forward to continuing patient enrollment to evaluate the use of this DCB in treating this challenging disease state.”

Critical limb ischemia with peripheral arterial disease is associated with non-healing wound ulcers and amputation, according to the Fridley, Minn.-based company.

“Patency rates after conventional balloon angioplasty can be challenging in BTK disease, and we believe that a sustained patency could improve healing and reduce the need of target lesions revascularization and major amputation,” Dr. Francesco Liistro, chief of cardiovascular intervention at San Donato Hospital, added. “Multiple studies have evaluated DCBs in the superficial femoral arteries, but the need for clinically supported treatment options for below-the-knee PAD still remains. We look forward to participating in this significant trial to evaluate the In.Pact 0.014 DCB in a complex CLI patient population, particularly given the strong evidence for use of In.Pact Admiral in the SFA.”

The In.Pact BTK study is slated to enroll 60 patients. The primary endpoint is late lumen loss at 9 months in patients who received the DCB compared to standard percutaneous transluminal angioplasty.

“Peripheral artery disease below the knee is complex. With these prior analyses, we have developed an unmatched knowledge around the treatment of below-the-knee disease and CLI,” VP and GM of Medtronic’s peripheral biz Mark Pacyna said. “Together with our clinical investigators, we look forward to launching the In.Pact BTK study to evaluate the effect of the In.Pact 0.014 in patients with below-the-knee PAD.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS